Skip to main content

Changes to Hepatitis C Agents Drug Class Effective January 2026

Last updated on

On January 1, 2026, the status of drugs in the hepatitis C agents class will change based on the recommendations from the Texas Drug Utilization Review Board meeting that was held on October 24, 2025.

Mavyret, Texas Medicaid’s preferred direct-acting antiviral drug option for treating hepatitis C infection, will no longer be the preferred drug.

Email vdp-formulary@hhs.texas.gov with comments or any questions.